Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 31.52% is 201% above its 5-year average of 10.48%, near the high end of its 5-year range (0.00%–41.71%).
33.06% above its 12-month average of 23.69%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 41.71%.
GROSS MARGIN
31.52%
GROSS MARGIN AVG TTM
23.69%
GROSS MARGIN AVG 3Y
16.72%
GROSS MARGIN AVG 5Y
10.48%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+33.06%
CURRENT VS 3Y AVG
+88.53%
CURRENT VS 5Y AVG
+200.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.69%
median of 509 covered companies
CURRENT VS SECTOR MEDIAN
-32.49%
vs the sector median at left
20/20 Biolabs Inc.
Market Cap
$4.42M
Gross Margin
31.52%
TTM Avg
23.69%
3Y Avg
16.72%
5Y Avg
10.48%
Market Cap
$4.54M
Gross Margin
26.32%
TTM Avg
-195.38%
3Y Avg
-178.16%
5Y Avg
-96.97%
Market Cap
$4.49M
Gross Margin
0.00%
TTM Avg
41.76%
3Y Avg
-40.89%
5Y Avg
-27.26%
Market Cap
$4.50M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.13M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
-19.05%
Market Cap
$4.63M
Gross Margin
100.00%
TTM Avg
99.28%
3Y Avg
89.13%
5Y Avg
81.38%
Market Cap
$4.80M
Gross Margin
19.34%
TTM Avg
59.23%
3Y Avg
54.62%
5Y Avg
36.41%
Market Cap
$4.81M
Gross Margin
100.00%
TTM Avg
50.00%
3Y Avg
43.60%
5Y Avg
29.07%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 20/20 Biolabs Inc. (AIDX) | $4.42M | 31.52% | 23.69% | 16.72% | 10.48% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.54M | 26.32% | -195.38% | -178.16% | -96.97% |
| GRI Bio, Inc. (GRI)vs › | $4.18M | N/A | 0.00% | 0.00% | 0.00% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.49M | 0.00% | 41.76% | -40.89% | -27.26% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.13M | 0.00% | 0.00% | 25.00% | -19.05% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.63M | 100.00% | 99.28% | 89.13% | 81.38% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.80M | 19.34% | 59.23% | 54.62% | 36.41% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.81M | 100.00% | 50.00% | 43.60% | 29.07% |
| CalciMedica, Inc. (CALC)vs › | $4.82M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
31.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 41.71% |
| 2026-03-31 | 17.80% |
| 2025-12-31 | 24.23% |
| 2025-09-30 | 34.71% |
| 2025-06-30 | 0.00% |
| 2024-12-31 | 30.41% |
| 2024-09-30 | 6.69% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 11.64% |
| 2023-03-31 | 0.44% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
